- Home
- NGNE vs HQL Comparison
NGNE vs HQL Comparison
Compare NGNE & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- HQL
- Stock Information
- Founded
- NGNE 2003
- HQL 1992
- Country
- NGNE United States
- HQL United States
- Employees
- NGNE N/A
- HQL N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- HQL Investment Managers
- Sector
- NGNE Health Care
- HQL Finance
- Exchange
- NGNE Nasdaq
- HQL Nasdaq
- Market Cap
- NGNE 471.1M
- HQL 377.2M
- IPO Year
- NGNE N/A
- HQL N/A
- Fundamental
- Price
- NGNE $20.30
- HQL $13.78
- Analyst Decision
- NGNE Strong Buy
- HQL
- Analyst Count
- NGNE 6
- HQL 0
- Target Price
- NGNE $60.80
- HQL N/A
- AVG Volume (30 Days)
- NGNE 600.4K
- HQL 120.9K
- Earning Date
- NGNE 11-18-2024
- HQL 01-01-0001
- Dividend Yield
- NGNE N/A
- HQL 11.56%
- EPS Growth
- NGNE N/A
- HQL N/A
- EPS
- NGNE N/A
- HQL 0.79
- Revenue
- NGNE $925,000.00
- HQL N/A
- Revenue This Year
- NGNE N/A
- HQL N/A
- Revenue Next Year
- NGNE N/A
- HQL N/A
- P/E Ratio
- NGNE N/A
- HQL $17.08
- Revenue Growth
- NGNE N/A
- HQL N/A
- 52 Week Low
- NGNE $12.49
- HQL $11.34
- 52 Week High
- NGNE $74.49
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- NGNE 32.31
- HQL 33.14
- Support Level
- NGNE $14.44
- HQL $13.68
- Resistance Level
- NGNE $43.24
- HQL $14.37
- Average True Range (ATR)
- NGNE 5.36
- HQL 0.27
- MACD
- NGNE -4.50
- HQL -0.10
- Stochastic Oscillator
- NGNE 9.76
- HQL 5.92
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.